Skip to main content

Lexeo to help launch spinout around RNA drugs for the heart

Submitted by admin on
snippet

Perceptive Xontogeny Venture Funds and venBio Partners are contributing up to $40 million to a spinout of genetic medicine maker Lexeo Therapeutics to that will aim to advance drugs for heart conditions.

Source
BioPharma Dive

Daiichi taps Nosis to deliver RNA therapies beyond the liver

Submitted by admin on
snippet

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver.

The Japanese drugmaker is best known for antibody-drug conjugates (ADCs), having secured deals with AstraZeneca and Merck & Co. and spawned the blockbuster Enhertu.

Source
Fierce Biotech

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

Submitted by admin on
snippet

Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

Source
Pharma Voice

Geneoscopy Prepares Launch of FDA-approved At-home RNA Colorectal Cancer Screening Test

Submitted by admin on
snippet

The St. Louis, MO-based test has 94% sensitivity for colorectal cancer detection. Colosense said it aims to transform gastrointestinal diagnostics, leveraging RNA technology for higher accuracy and ease of use.

Source
Medical Devices and Diagnostics Industry

GSK taps Rgenta to develop new RNA-targeting treatments, offering up to $500M per target

Submitted by admin on
snippet

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. The new partners aim to develop new splice modulators for multiple disease areas, including oncology, with Rgenta able to receive up to nearly $500 million biobucks per target.

Source
Fierce Biotech

An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond

Submitted by admin on
snippet

The 2020s are shaping up to be a golden age for RNA. From COVID-19 vaccines to rare disease treatments, RNA has become key to tackling many of biotech’s tough obstacles.

Stoke Therapeutics is bringing that RNA revolution to difficult neurological diseases that primarily affect children, including the severe form of epilepsy called Dravet syndrome, the genetic cause of which has only recently been understood, said Stoke CEO Dr. Ed Kaye.

Source
Pharma Voice

CAMP4 is latest biotech to eye IPO, while Upstream spells out $182M plans

Submitted by admin on
snippet

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its own ambitions at $182 million.

Source
Fierce Biotech

Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney

Submitted by admin on
snippet

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

Source
BioPharma Dive

Eli Lilly unwraps $700M nucleic acid R&D center in Boston Seaport, opens doors to biotechs

Submitted by admin on
snippet

Eli Lilly has opened a $700 million R&D center in the Boston Seaport, boosting its RNA and DNA research capabilities and expanding its biotech-hosting Gateway Labs to the East Coast for the first time.

Source
Fierce Biotech
News Tags

Triastek and BioNTech to develop 3D-printed RNA therapeutics

Submitted by admin on
snippet

BioNTech and Triastek have entered a research partnership and platform technology licence agreement focusing on the development of 3D-printed oral RNA therapeutics.

The companies will create RNA therapeutics to be delivered orally, using 3D printing technology.

Source
Pharmaceutical Technology